Over the year multiple clinical trial readouts validated the use of MRD for multiple indications, while companies in the space began to consolidate.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...
The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by the ...
WASHINGTON, D.C. [May 6, 2025] — The National Comprehensive Cancer Network ® (NCCN ®) hosted an Oncology Policy Summit in Washington, D.C., today, focused on improving care coordination between ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback